In the past week, AKYA stock has gone up by 12.28%, with a monthly gain of 4.19% and a quarterly plunge of -24.45%. The volatility ratio for the week is 7.04%, and the volatility levels for the last 30 days are 5.28% for Akoya Biosciences Inc The simple moving average for the past 20 days is 13.27% for AKYA’s stock, with a -5.62% simple moving average for the past 200 days.
Is It Worth Investing in Akoya Biosciences Inc (NASDAQ: AKYA) Right Now?
Additionally, the 36-month beta value for AKYA is 1.54. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AKYA is 21.41M and currently, short sellers hold a 4.72% ratio of that float. The average trading volume of AKYA on May 10, 2024 was 162.60K shares.
AKYA) stock’s latest price update
Akoya Biosciences Inc (NASDAQ: AKYA)’s stock price has gone rise by 9.00 in comparison to its previous close of 4.11, however, the company has experienced a 12.28% increase in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-06 that Akoya (AKYA) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts’ Opinion of AKYA
JP Morgan, on the other hand, stated in their research note that they expect to see AKYA reach a price target of $18. The rating they have provided for AKYA stocks is “Overweight” according to the report published on July 05th, 2023.
UBS gave a rating of “Buy” to AKYA, setting the target price at $14 in the report published on February 02nd of the previous year.
AKYA Trading at -0.55% from the 50-Day Moving Average
After a stumble in the market that brought AKYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.09% of loss for the given period.
Volatility was left at 5.28%, however, over the last 30 days, the volatility rate increased by 7.04%, as shares surge +4.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.85% lower at present.
During the last 5 trading sessions, AKYA rose by +12.28%, which changed the moving average for the period of 200-days by -33.83% in comparison to the 20-day moving average, which settled at $3.96. In addition, Akoya Biosciences Inc saw -8.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKYA starting from McKelligon Brian, who sale 7,500 shares at the price of $4.97 back on Mar 20 ’24. After this action, McKelligon Brian now owns 231,868 shares of Akoya Biosciences Inc, valued at $37,243 using the latest closing price.
McKelligon Brian, the President and CEO of Akoya Biosciences Inc, sale 7,500 shares at $4.94 during a trade that took place back on Mar 13 ’24, which means that McKelligon Brian is holding 224,368 shares at $37,035 based on the most recent closing price.
Stock Fundamentals for AKYA
Current profitability levels for the company are sitting at:
- -0.59 for the present operating margin
- 0.56 for the gross margin
The net margin for Akoya Biosciences Inc stands at -0.66. The total capital return value is set at -0.39. Equity return is now at value -112.72, with -35.53 for asset returns.
Based on Akoya Biosciences Inc (AKYA), the company’s capital structure generated 0.59 points at debt to capital in total, while cash flow to debt ratio is standing at -0.65. The debt to equity ratio resting at 1.46. The interest coverage ratio of the stock is -13.27.
Currently, EBITDA for the company is -47.14 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 2.32. The receivables turnover for the company is 5.69for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.45.
Conclusion
In conclusion, Akoya Biosciences Inc (AKYA) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
